Wan‐Ru Zhang

South China Institute of Collaborative Innovation

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Yong Yang

Shanghai Jiao Tong University

Yue‐Ping Liu

Chinese Academy of Medical Sciences & Peking Union Medical College

Dong‐Hua Luo

Sun Yat-sen University

Yongwen Song

Chinese Academy of Medical Sciences & Peking Union Medical College

Dongmei Mai

Sun Yat-sen University

Bo Chen

Gansu University of Traditional Chinese Medicine

Xin Liu

Kunming Medical University

Yuan Tang

Chinese Academy of Medical Sciences & Peking Union Medical College

Ning Li

Chinese Academy of Medical Sciences & Peking Union Medical College

Jing Jin

Peking Union Medical College Hospital

Cooperative Institutions

Chinese Academy of Medical Sciences & Peking Union Medical College

South China Institute of Collaborative Innovation

Peking Union Medical College Hospital

Sun Yat-sen University

Sun Yat-sen University Cancer Center

National Clinical Research

State Key Laboratory of Oncology in South China

Cancer Hospital of Chinese Academy of Medical Sciences

Central South University

Key Laboratory of Guangdong Province

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Prediction of 5‐year overall survival of diffuse large B‐cell lymphoma on the pola‐R‐CHP regimen based on 2‐year event‐free survival and progression‐free survival

Cancer Medicine (2024)

Wan‐Ru Zhang Xin Liu Qiuzi Zhong Tao Wu Yong Yang

Abstract This study aimed to predict the 5‐year overall survival (OS) benefit of pola‐R‐CHP versus R‐CHOP in the POLARIX trial based on the 2‐year event‐free survival (EFS) and progression‐free survival (PFS) rates in diffuse large B‐cell lymphoma (DLBCL). We identified randomized controlled trials (RCT) published before 31 May 2023. The correlation between the logarithmic (log) hazard ratio (HR) for EFS (HR EFS ) or PFS (HR PFS ) and the HR for OS (HR OS ) was estimated at the trial‐level. Correlation analysis was performed between 2‐year PFS or EFS and 5‐year OS rates at the treatment arm‐level. Linear regression models were used to calculate the 5‐year OS of pola‐R‐CHP and R‐CHOP. In the included 20 RCTs, a linear correlation between HR EFS ( r = 0.765) or HR PFS ( r = 0.534) and HR OS was observed at the trial‐ level. Two‐year EFS ( r = 0.918) or 2‐year PFS ( r = 0.865) correlated linearly with 5‐year OS. Linear regression analysis between 2‐year EFS/PFS and 5‐year OS gave estimated 5‐year OS rates between pola‐R‐CHP and R‐CHOP of 6.4% and 6.3%, respectively. Two‐year EFS and PFS are feasible early endpoints in patients with DLBCL treated primarily with immunochemotherapy. The pola‐R‐CHP regimen is expected to improve 5‐year OS.

Regimen

Progression-free survival

10.1002/cam4.6899

Cite

Citations (3)

Combining pretreatment plasma Epstein‐Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study

Cancer Medicine (2019)

Yu‐Yun Du Dong‐Hua Luo Xuesong Sun Lin‐Quan Tang Hai‐Qiang Mai

This study aimed to evaluate the prognostic value of combining pretreatment Epstein-Barr virus (EBV) DNA level and cervical node necrosis (CNN) for patients with nasopharyngeal carcinoma (NPC) receiving intensity-modulated radiotherapy (IMRT). A total of 607 incident nonmetastatic NPC patients treated with IMRT ± chemotherapy were reviewed. Patients were divided into four groups based on EBV DNA level and CNN status. The primary endpoint was progression-free survival (PFS). Kaplan-Meier curves with log-rank test were applied to compare survival outcomes and the Cox proportional model was used to identify independent prognostic factors. Pretreatment EBV DNA level and CNN status were independent prognostic factors. Patients in the low-level EBV DNA group or non-CNN group had significantly better 5-year PFS. Multivariate analyses demonstrated that CNN was an independent prognostic factor for overall survival (OS) (HR = 1.927, 95% CI: 1.129-3.290, P = .016), PFS (HR = 1.492, 95% CI: 1.005-2.214, P = .047), distant metastasis-free survival (DMFS) (HR = 1.661, 95% CI: 1.044-2.644, P = .032), but not locoregional relapse-free survival. EBV DNA levels correlated significantly with CNN with a correlation coefficient of .324 (P < .001). Compared with low-level EBV DNA and non-CNN grouping, high-level EBV DNA and CNN grouping had poor PFS. The combined classification was an independent prognostic factor for OS (P < .001), PFS (P = .001), and DMFS (P = .018). Pretreatment plasma EBV DNA level and CNN status both closely correlated with prognosis of NPC patients in the IMRT era. Combined EBV DNA level and CNN status improves risk stratification and prognostic value.

10.1002/cam4.2481

Cite

Citations (26)